Davis Capital Management Makes New $647,000 Investment in Kenvue Inc. $KVUE

Davis Capital Management purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,872 shares of the company’s stock, valued at approximately $647,000.

A number of other large investors also recently modified their holdings of the company. Financiere des Professionnels Fonds d investissement inc. increased its holdings in Kenvue by 13.4% in the 3rd quarter. Financiere des Professionnels Fonds d investissement inc. now owns 465,660 shares of the company’s stock worth $7,558,000 after purchasing an additional 55,050 shares in the last quarter. Generali Asset Management SPA SGR grew its holdings in shares of Kenvue by 3.9% during the third quarter. Generali Asset Management SPA SGR now owns 156,915 shares of the company’s stock worth $2,547,000 after purchasing an additional 5,843 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the third quarter valued at approximately $25,000. Mather Group LLC. raised its holdings in Kenvue by 144.9% in the 3rd quarter. Mather Group LLC. now owns 30,169 shares of the company’s stock valued at $490,000 after buying an additional 17,849 shares during the last quarter. Finally, Renaissance Capital LLC boosted its position in Kenvue by 55.8% during the 3rd quarter. Renaissance Capital LLC now owns 980,436 shares of the company’s stock worth $15,912,000 after buying an additional 351,259 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 0.3%

Shares of NYSE:KVUE opened at $17.30 on Friday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The business’s 50-day moving average is $16.66 and its 200-day moving average is $18.56. The company has a market capitalization of $33.15 billion, a price-to-earnings ratio of 23.07 and a beta of 0.60.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on KVUE shares. Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Barclays lifted their target price on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Citigroup decreased their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Redburn Partners set a $22.00 price objective on Kenvue in a research report on Friday, September 26th. Finally, Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.23.

Insider Transactions at Kenvue

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of Kenvue stock in a transaction on Friday, December 12th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.68% of the stock is currently owned by corporate insiders.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.